Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].

Torsten Haferlach1, Ulrike Bacher, Wolfgang Kern

  • 1MLL Münchner Leukämielabor GmbH, München. torsen.haferlach@mll-online.com

Medizinische Klinik (Munich, Germany : 1983)
|September 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosis.

Leukemia·2026
Same author

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

Leukemia·2026
Same author

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

HemaSphere·2026
Same author

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Clinical epigenetics·2026
Same author

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Leukemia·2026
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014
See all related articles

Philadelphia-negative chronic myeloproliferative diseases (CMPD) diagnostics are evolving. Molecular markers like JAK2 mutations are crucial for accurate classification and targeted therapies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Context:

  • Philadelphia-negative chronic myeloproliferative diseases (CMPD) are complex and heterogeneous disorders.
  • WHO classification includes polycythemia vera (PV), chronic idiopathic myelofibrosis (CIMF), essential thrombocythemia (ET), and others.
  • Traditional diagnostics relied on clinical and morphological aspects.

Purpose:

  • To highlight the evolving diagnostic landscape of CMPD.
  • To emphasize the integration of molecular diagnostics alongside traditional methods.
  • To underscore the importance of molecular markers for prognosis and targeted therapy.

Summary:

  • Recent advancements include cytogenetics, FISH, and molecular characterization, notably the JAK2V617F mutation.

Related Experiment Videos

  • Mutations in JAK2 exon 12 and MPL further expand the understanding of CMPD.
  • In chronic eosinophilic leukemia/hypereosinophilic syndrome (CEL/HES), FIP1L1-PDGFRA fusion gene detection guides targeted tyrosine kinase inhibitor therapy.
  • Diagnostics are shifting towards a multimodal approach combining morphology, cytogenetics, and molecular methods.

    • Impact:

    • Enables more precise classification and prognostication of CMPD.
    • Facilitates the development and application of targeted therapies, improving patient outcomes.
    • Establishes a multimodal diagnostic algorithm for comprehensive CMPD evaluation.